LIXT.NASDAQLixte Biotechnology Holdings, INC
S-1/A: Lixte Biotechnology Holdings Eyes $4 Million in Unit Offering to Bolster Cancer Therapy Development
Sentiment:
Amendment to Registration Statement
Lixte Biotechnology Holdings is undertaking a best efforts offering of units, consisting of common stock or pre-funded warrants and common warrants, aiming to raise up to $4 million for working capital and general corporate purposes.
Delay expectedThe company provided notice to the City of Hope National Medical Center of the Companys intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024 due to the lack of patient accrual.
Capital raiseLixte Biotechnology Holdings is offering up to 1,895,734 units, each comprising one share of common stock or a pre-funded warrant and 1.25 common stock purchase warrants, at an assumed price of $2.11 per unit.The offering aims to raise gross proceeds of approximately $4 million.Each common warrant is immediately exercisable at a price equal to 110% of the offering price per unit and expires five years from the issuance date.Investors can opt for pre-funded warrants instead of common stock to avoid exceeding a 4.99% beneficial ownership threshold.The company intends to use the net proceeds for working capital and general corporate purposes.The offering is on a reasonable best efforts basis with no minimum amount required to be sold.
Worse than expectedThe company has a history of operating losses and may never achieve profitability.The company's auditor has expressed substantial doubt about its ability to continue as a going concern.The company is not currently in compliance with Nasdaq continued listing requirements.
Summary
- Lixte Biotechnology Holdings is offering up to 1,895,734 units, each comprising one share of common stock or a pre-funded warrant and 1.25 common stock purchase warrants, at an assumed price of $2.11 per unit.
- The offering aims to raise gross proceeds of approximately $4 million.
- Each common warrant is immediately exercisable at a price equal to 110% of the offering price per unit and expires five years from the issuance date.
- Investors can opt for pre-funded warrants instead of common stock to avoid exceeding a 4.99% beneficial ownership threshold.
- The company intends to use the net proceeds for working capital and general corporate purposes.
- The offering is on a reasonable best efforts basis with no minimum amount required to be sold.
- The company has granted WallachBeth Capital LLC a right of first refusal for future equity and debt offerings for three months following the closing of this offering.
- The company is currently not in compliance with the Nasdaq continued listing requirements and has until February 18, 2025 to regain compliance.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While the company is pursuing promising cancer therapies and has ongoing clinical trials, it faces significant financial challenges, including a history of losses, going concern doubts, and Nasdaq compliance issues. The potential for a capital raise is a positive, but the risks associated with the company's financial situation and the inherent uncertainties of drug development temper the overall sentiment.
Positives
- The offering could provide the company with additional capital to fund its operations and clinical trials.
- The company has a license agreement with the National Institute of Health.
- The company has several ongoing clinical trials for its lead compound LB-100.
- The company has a collaboration agreement with the Spanish Sarcoma Group.
- The company has a clinical trial agreement with the Netherlands Cancer Institute.
Negatives
- The company has a history of operating losses and may never achieve profitability.
- The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
- The company is not currently in compliance with Nasdaq continued listing requirements.
- The company may not sell all of the units offered, which would reduce the amount of proceeds received.
- The company's management will have broad discretion over the use of the proceeds.
- The company's securities are speculative and involve a high degree of risk.
- The company's colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious Adverse Events (SAEs) observed in the clinical trial that was launched in August 2024.
Risks
- The company may not be successful in its efforts to develop a portfolio of commercially viable products.
- The company needs significant additional financing to fund its operations and complete the development of its lead product candidate, LB-100.
- The company might find it difficult to enroll patients in its clinical trials.
- The results of preclinical studies or earlier clinical trials are not necessarily predictive of future results.
- The company's lead product candidate and future product candidates could fail to receive regulatory approval from the FDA.
- The company faces substantial competition, which might result in others discovering, developing or commercializing products before or more successfully than the company does.
- The company is a smaller reporting company and has elected to comply with certain reduced reporting and disclosure requirements which could make its common stock less attractive to investors.
- The company's shares of common stock could be delisted from Nasdaq, which could affect its market price and liquidity and reduce its ability to raise capital.
- A clinical trial hold due to serious adverse events could delay or halt the development of our product candidate.
Future Outlook
The company expects its operating losses will continue, or even increase, at least through the near term. The company's longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer.
Industry Context
The company operates in the biopharmaceutical industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The company is focused on developing cancer therapies, a market with significant unmet medical needs and substantial commercial potential.
Comparison to Industry Standards
- Lixte is a clinical-stage biopharmaceutical company, similar to companies like BioNTech, Moderna, and Inovio Pharmaceuticals.
- LB-100, Lixte's lead compound, is being tested in clinical trials for various cancers, similar to how Amgen's Lumakras is being tested for non-small cell lung cancer.
- Lixte's approach of enhancing existing therapies with LB-100 is similar to strategies employed by companies like Exelixis, which combines its Cabozantinib with other therapies.
- The company's reliance on strategic partnerships and licensing agreements is a common practice in the industry, similar to how Roche collaborates with other companies to develop and commercialize its drugs.
- The company's focus on protein phosphatase 2A (PP2A) inhibitors is a novel approach, but it carries the risk of potential toxicity, similar to other targeted therapies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and Chief Executive Officer | John S. Kovach | Bastiaan van der Baan | September 26, 2023 | John S. Kovach passed away on October 5, 2023. |
| Chairman of the Board of Directors | Unknown | Bastiaan van der Baan | October 6, 2023 | Bastiaan van der Baan was appointed as Chairman of our Board of Directors. |
Stakeholder Impact
- Shareholders: Potential dilution from the offering, but also potential upside if the company is successful in developing and commercializing its therapies.
- Employees: Continued employment and potential for growth if the company is successful.
- Customers: Potential for new and improved cancer therapies.
- Suppliers: Continued business relationship with the company.
- Creditors: Increased risk of default if the company is not successful in raising capital and generating revenue.
Next Steps
- Complete the offering of units and receive the net proceeds.
- Use the net proceeds for working capital and general corporate purposes.
- Continue to enroll patients in ongoing clinical trials.
- Regain compliance with Nasdaq listing rules by February 18, 2025.
- Decide whether to proceed to a related Phase 2 portion of the study at that time.
Key Dates
| Date | Description |
|---|---|
| March 22, 2006 | Research on the LB-100 series was initiated under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH |
| June 30, 2006 | Pursuant to a share exchange agreement, we acquired all of the outstanding shares of Lixte Biotechnology, Inc. which then became a wholly owned subsidiary. |
| December 7, 2006 | We changed our name to Lixte Biotechnology Holdings, Inc. |
| July 31, 2019 | We entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group (Grupo Espaol de Investigacin en Sarcomas or GEIS), Madrid, Spain |
| March 9, 2021 | The clinical trial was initiated on March 9, 2021. However, due to the lack of patient accrual, the Company provided notice to the City of Hope National Medical Center of the Companys intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024. |
| October 13, 2022 | We announced that the Spanish Agency for Medicines and Health Products (Agencia Espaola de Medicamentos y Productos Sanitarios or AEMPS) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS). |
| April 2023 | GEIS completed its first site initiation visit in preparation for the clinical trial at Fundacin Jimnez Daz University Hospital (Madrid). |
| June 2, 2023 | We effected a one-for-ten reverse split of our outstanding shares of common stock in order to remain in compliance with the $1.00 minimum closing bid price requirement of Nasdaq. |
| June 30, 2023 | The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose of the combination of doxorubicin and LB-100. |
| July 20, 2023 | In a private placement offering to the institutional investor that was concurrent to as registered direct offering of our securities on July 20, 2023, the Company also sold Warrants to purchase 583,334 shares of common stock. |
| September 20, 2023 | We announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (PD-1) blocking antibody of GSK plc (GSK), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). |
| September 26, 2023 | Bastiaan van der Baan replaced our founder, John S. Kovach, as President and Chief Executive Officer. |
| October 5, 2023 | Dr. Kovach passed away on October 5, 2023. |
| October 6, 2023 | Mr. van der Baan was appointed as Chairman of our Board of Directors. |
| January 29, 2024 | We announced the entry of the first patient into this clinical trial. |
| February 23, 2024 | We entered into a Patent License Agreement (the License Agreement) with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH). |
| June 10, 2024 | We entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (NKI) to conduct a Phase 1b clinical trial of the Companys protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (Roche), for patients with microsatellite stable metastatic colon cancer. |
| June 30, 2024 | The recruitment phase of the Phase 1b portion of the protocol was completed during the quarter ended June 30, 2024. |
| July 8, 2024 | The Company provided notice to the City of Hope National Medical Center of the Companys intent to terminate the Clinical Research Support Agreement effective as of July 8, 2024. |
| August 2024 | This Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment of patients with metastatic microsatellite stable colorectal cancer. The clinical trial opened in August 2024 with the enrollment of the first patient. |
| August 19, 2024 | We received a deficiency letter from the Listing Qualifications Department of Nasdaq indicating that we are not in compliance with Nasdaq Listing Rule 5550(b)(1) (the Stockholders Equity Rule), which requires us to maintain a minimum stockholders equity of $2,500,000. |
| October 3, 2024 | We submitted a letter to Nasdaq with our plan to regain compliance with the Stockholders Equity Rule, which outlined our proposed initiatives to regain compliance by raising equity capital through various registered equity offerings. |
| October 21, 2024 | Nasdaq provided us notice that it had granted an extension through February 18, 2025 to regain compliance with the Stockholders Equity Rule. |
| October 31, 2024 | The closing price of our common stock on Nasdaq on October 31, 2024 was $2.11 per share. |
| November 30, 2024 | This offering will end no later than November 30, 2024, unless we decide to terminate the offering earlier (which we may do at any time at our discretion) prior to that date. |
| December 31, 2026 | This clinical trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026. |
| December 31, 2027 | We currently expect that this clinical trial will be completed by December 31, 2027. |
Keywords
Lixte Biotechnology, unit offering, common stock, pre-funded warrants, common warrants, LB-100, clinical trials, cancer therapy, WallachBeth Capital, Nasdaq
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.